Journal
CLINICAL INFECTIOUS DISEASES
Volume 62, Issue -, Pages S318-S325Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciw044
Keywords
HBV; eradication; exhaustion
Categories
Funding
- CDC Foundation
- Gilead
Ask authors/readers for more resources
Chronic hepatitis B infection affects > 300 million people worldwide and is a leading cause of liver failure and cancer. Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B virus (HBV) DNA with the use of nucleoside analogues. Chronic suppressive therapy rarely results in a functional cure or absence of detectable HBV DNA in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy. The major obstacles to achieving a functional cure are the presence of covalently closed circular DNA and ineffective/exhaustive immune system. This review focuses on novel approaches to target viral life cycle and host immunity to achieve a functional cure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available